Analyst Research

Report Title Price
Provider: Wright Reports
$75.00
Provider: S&P Capital IQ Quantitative Report
$127.00
Provider: Stock Traders Daily
$20.00
Provider: Stock Traders Daily
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Vertex Pharmaceuticals Inc Lowers High End Of Prior FY 2013 Revenue Guidance


Monday, 29 Jul 2013 04:00pm EDT 

Vertex Pharmaceuticals Inc updated its guidance for total fiscal 2013 revenues and expects total revenues to be in the range of $1.10 billion to $1.2 billion. The prior range, provided on January 29, 2013, was for total 2013 revenues to be in the range of $1.10 to $1.25 billion. According to I/B/E/S Estimates, analysts were expecting the Company to report revenue of $1.19 billion for fiscal 2013. 

Company Quote

29.5
0.09 +0.31%
29 Aug 2014